Duluth Holdings: Fiscal 3Q Earnings Snapshot

Associated Press |

BELLEVILLE, Wis. (AP) _ Duluth Holdings Inc. (DLTH) on Thursday reported a loss of $3.2 million in its fiscal third quarter.

On a per-share basis, the Belleville, Wisconsin-based company said it had a loss of 10 cents.

The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for a loss of 10 cents per share.

The clothing and tools supplier posted revenue of $106.7 million in the period, which topped Street forecasts. Five analysts surveyed by Zacks expected $104.7 million.

Duluth Holdings expects full-year earnings to be 79 cents to 84 cents per share, with revenue in the range of $555 million to $575 million.

Duluth Holdings shares have increased 74 percent since the beginning of the year. The stock has climbed 66 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on DLTH at https://www.zacks.com/ap/DLTH

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor, Equities.com; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.